IL6 and endothelial dysfunction: Notably, the significant risk reduction in solid tumor patients versus hematologic malignancies may reflect differential inflammatory states, as elevated interleukin-6 levels in hematologic malignancies are known to promote endothelial dysfunction, which further supported the results of Wang et al. [25].